---
layout: post
title: "科伦药业：创新药物SKB264（TROP2-ADC）治疗晚期三阴性乳腺癌III期临床获批开展"
date: 2022-04-07 16:10:11 +0800
categories: zhengquanshibao·egongsi
tags: 证券时报·e公司新闻
---
<!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/0.002422" data-code="002422|0|2" data-code2="002422|0|6|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=0.002422&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 002422_0" data-code="K 002422|0|2" data-code2="K 002422|0|6|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>科伦药业(002422)4月7日晚间公告，公司控股子公司科伦博泰开发的创新药物TROP2抗体偶联药物SKB264(TROP2-ADC)治疗至少经二线治疗失败的晚期或转移性三阴性乳腺癌(TNBC)患者以随机对照试验(RCT)支持上市申请的III期临床试验获得国家药品监督管理局药品审评中心同意开展。</p><p class="em_media">（文章来源：证券时报）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204072335168554>

[返回证券时报·e公司新闻](//finews.withounder.com/category/zhengquanshibao·egongsi.html)｜[返回首页](//finews.withounder.com/)